Journal of Applied Toxicology

Oncolytic virus preclinical toxicology studies

Rigvir has once again received international confirmation that it is non-toxic, has high tolerability and does not induce any severe adverse event even at increased doses.

1 December 2022

The search for treatments as safe as possible is a priority in medical care, especially in cancer care, where therapies often go hand in hand with severe side effects. Oncolytic virotherapy is promising in both safety and efficacy. Many currently ongoing clinical trials demonstrate the growing interest in this field. To conduct clinical trials, preclinical studies are mandatory, however there are not many reviews of toxicology studies on oncolytic virus therapies. This article summarizes the preclinical toxicology studies of several oncolytic viruses in different stages of development. Considering that the adverse events were mostly minor and reversible, it is concluded that oncolytic viruses have low toxicity and good tolerability in animals. Rigvir compared to other viruses, was shown to persist in the body for a shorter period of time at all dose levels administered. Regarding basic toxicology studies, Rigvir, even at the highest dose tested, showed high tolerability and did not induce any severe adverse event, unlike some of the genetically modified viruses.

Full Article:

Contacts for Media Inquiries

Rigvir Group